Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Open Label, Phase II Trial Comparing Rituximab Plus Sargramostim to Rituximab Monotherapy for the Treatment of Relapsed Follicular B-Cell Lymphoma.

Trial Profile

Randomized, Open Label, Phase II Trial Comparing Rituximab Plus Sargramostim to Rituximab Monotherapy for the Treatment of Relapsed Follicular B-Cell Lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2013

At a glance

  • Drugs Rituximab (Primary) ; Sargramostim (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms PREMIER
  • Sponsors Bayer; Berlex Inc
  • Most Recent Events

    • 13 Apr 2010 'Genzyme Corporation' added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
    • 13 Apr 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top